To investigate the trend of the posthepatectomy survival outcomes of hepatocellular carcinoma (HCC) patients by analysis of a prospective cohort of 1198 patients over a 20-year period. Background: The hospital mortality rate of hepatectomy for HCC has improved but the long-term survival rate remains unsatisfactory. We reported an improvement of survival results 10 years ago. It was not known whether there has been further improvement of results in recent years. Methods: The patients were categorized into two 10-year periods: period 1, before 1999 (group 1, n = 390) and period 2, after 1999 (group 2, n = 808). Patients in group 2 were managed according to a modified protocol and technique established in previous years. Results: The patients in group 2 were older and had a higher incidence of comorbid illness and cirrhosis. They had a lower hospital mortality rate (3.1% vs 6.2%, P = 0.012) and longer 5-year overall survival (54.8% vs 42.1%, P < 0.001) and disease-free survival rates (34.8% vs 24%, P = 0.0024). An improvement in the overall survival rate was observed in patients with cirrhosis, those undergoing major hepatectomy, and those with tumors of tumor-nodemetastasis stages II, IIIA, and IVA. A significant increase in the survival rates was also seen in patients whose tumors were considered transplantable by the Milan criteria (72.5% vs 62.7%, P = 0.0237). Multivariate analysis showed a significantly more favorable patient survival for hepatectomy in period 2. Conclusions: A continuous improvement of survival outcomes after hepatectomy for HCC was achieved in the past 20 years even in patients with advanced diseases. Hepatectomy remains the treatment of choice for resectable HCC in a predominantly hepatitis B virus-based Asian population. (Ann Surg 2011;253:745-758) H epatocellular carcinoma (HCC) is one of the most lethal malignancies. Liver transplantation is the best treatment for HCC but is limited by the number of deceased organ donations. Even with the application of living donor liver transplantation, not many patients can benefit from the procedure. 1 In Asia, resection of HCC remains the treatment of choice for potentially curable diseases. Resection of HCC is not without risk, especially in the presence of cirrhosis. Nevertheless, the results of resection of HCC have been steadily improving. In 1999, we reported the first series of hepatectomy for HCC From the
without hospital mortality. 2 In 2000, we reported an improved longterm survival rate over a 10-year period. 3 In the last 10 years, we continued to refine the surgical technique, expand the indications of hepatectomy and improve perioperative care. This study evaluated whether there was further improvement of the survival results since our last reports.
PATIENTS AND METHODS
Between 1989 and 2008, 1198 consecutive patients underwent resection of HCC at the Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China. The patients were managed and operated according to a protocol previously established. 2 Further modifications have been made in recent years ( Table 1 ). All data were collected prospectively by a single research assistant. The patients were categorized into two 10-year periods: before December 1998 (period 1, patients designated as group 1, n = 390) and after January 1999 (period 2, patients designated as group 2, n = 808).
Preoperative Management
The patients were selected for resection based on assessments of the general condition, tumor status, liver function, and remnant liver volume. The criteria for resectability on imaging were absence of extrahepatic metastasis, anatomically suitable and technically feasible disease, and absence of main portal vein or inferior vena cava (IVC) tumor thrombus. Involvement of the first-ordered branch of the portal vein to the junction with the contralateral branch and common hepatic duct and bilobed involvement did not preclude resection. Partial resection of the IVC was performed if the IVC was invaded by the tumor. A tumor near to the main drainage vein of the remnant liver was accepted for major hepatectomy if reconstruction of the hepatic vein was technically feasible. Computed tomography (CT) volumetry was performed if the remnant liver volume was estimated insufficient for postoperative recovery. Patients with remnant liver volume less than 30% underwent portal vein embolization of the ipsilateral lobe to induce contralateral lobe hypertrophy. 4 Liver function assessment was based largely on the results of the indocyanine green (ICG) clearance test. An ICG retention rate of 14% at 15 minutes after intravenous injection was acceptable for major hepatectomy. For minor hepatectomy, the cut-off value was 22%. 5 On the day before surgery, the patient was given a light meal. In the evening, the bowel was washed out with phosphosoda buffered oral saline laxative (Fleet; CB Fleet Co, Inc, Lynchburg, VA). Bowel washout was performed in case en bloc resection of the HCC with the colon was required and it could also reduce the discomfort arising from poor bowel movement in the immediate postoperative period. Antibiotic and a proton pump inhibitor were given at the time of induction of general anesthesia.
Surgical Techniques
Surgery was performed through a bilateral subcostal incision with an upward midline incision in most of the patients. Intraoperative ultrasonography was performed routinely as in the previous protocol to detect additional tumors in the liver, to define the topographic relationship of the tumor with major vascular pedicles and its possible invasion, and to determine the plane of liver transection and the width of the tumor-free resection margin. 2 Liver transection was performed mainly with the ultrasonic dissector. In period 2, a new model of ultrasonic dissector was used. The change included an incorporation of electrocautery into the tip of the instrument and reduction in the lumen size of the ultrasonic dissector tip from 2 mm to 1 mm, which allowed precise dissection of intrahepatic structures and immediate coagulation of fine branches exposed by the ultrasonic dissector. The use of the ultrasonic dissector allowed exposure of major intrahepatic portal pedicles and hepatic vein that served as an important anatomic landmark for a precise hepatectomy. 6 During the operation, meticulous attention was paid to protect the liver remnant by avoiding prolonged liver rotation and liver compression by the retractor and inflow vascular occlusion. Preservation or reconstruction of the major hepatic vein was also required to avoid liver congestion. 7 Liver rotation from the right side to the left side for exposure of the IVC and resection of a tumor in the segment 6 or 7 was intermittent, similar to the Pringle maneuver. During liver transection, the central venous pressure was maintained at a low level (<5 mm Hg) by restricting intravenous fluid administration to reduce bleeding. 8 Fluid replacement was performed once the liver transection was completed. Intermittent Pringle maneuver was not employed routinely in period 2 unless the liver transection was difficult due to venous congestion and inability to reduce the central venous pressure (in the situation of concomitant cardiac valvular disease or elderly patients). Hemostasis was achieved by electrocautery, argon beam coagulation and suturing. Argon beam coagulation was avoided at the site of suturing to reduce the chance of dislodgment of ligature. Large bite suturing was avoided to reduce the errors of occluding the major hepatic vein or its branches. Bile leakage from the transection surface, hilar plate and portal pedicle was checked by dilute methylene blue instillation into the bile duct via a cystic duct cannula (without common bile duct occlusion) or by compression onto the transection surface by a piece of clean gauze. Thorough irrigation was made to remove debris and clots. The wound was not closed until a pool of irrigant at the site of transection was totally clear. Abdominal drain was not deployed unless there was doubt about bile leakage. 9 Before wound closure, local anesthetic (bupivacaine, 3 mg/kg) was used to infiltrate the wound at the plane between the peritoneum and abdominal muscle.
Postoperative Care
After surgery, the patients, particularly those with cirrhosis and major hepatectomy, were monitored in the intensive care unit (ICU) with attention to the fluid balance, oxygenation, and tissue perfusion. Patients with evidence of fluid retention, low urine outputs and low blood pressure were treated with low-dose noradrenaline rather than further fluid administration. Mechanical ventilation was given to patients after a prolonged operation, marginal liver function, and unstable hemodynamics. All patients were given albumin and antibiotic for about 3 days. More potent antibiotic was given promptly once a sign of sepsis was detected. Incentive spirometry was performed in all patients to prevent atelectasis and pneumonia. Parenteral nutrition consisting of branched-chained amino acid-enriched solution, low-dose dextrose, medium-and long-chain triglycerides and phosphate was started immediately after hepatectomy in all patients with cirrhosis or major hepatectomy and was continued for 5 to 7 days by means of a central venous catheter inserted aseptically. 10 Once parenteral nutrition was started, no other intravenous fluid was given so as to avoid liver congestion. For patients with diabetes mellitus and receiving parenteral nutrition, tight blood glucose control was achieved to reduce infection. 11
Adjuvant Therapy
Postoperative adjuvant treatment for HCC was normally not given except in special circumstances. In group 1, 14 patients received chemoembolization for histologic margin involvement by the tumor and 30 patients were enrolled in a randomized trial of systemic epirubicin and chemoembolization. 12 In group 2, 40 patients received interferon in a randomized trial and 4 patients received chemoembolization for involvement of resection margin by the tumor. 13
Follow-up and Management of Recurrence
All patients were followed up by the surgical team monthly in the first year and quarterly thereafter if no recurrence was detected. Only 25 patients defaulted the follow-up. The first CT or magnetic resonance imaging was performed about 1 month after hepatectomy and repeated about every 3 to 4 months in the first year and every 6 months in subsequent years. The diagnosis of recurrence was based on typical imaging findings on CT or magnetic resonance imaging, and if necessary, percutaneous fine-needle aspiration cytology. Recurrences were treated aggressively using the multimodality approach. Patients with anatomically resectable tumors and preserved liver function would be considered for reresection. Otherwise, the tumors were treated by chemoembolization, alcohol injection, radiofrequency ablation, high intensity focused ultrasound 14 or liver transplantation, depending on the location of the tumor and the liver function of the patient. Patients with extrahepatic recurrence were treated by resection if the lesion was solitary and anatomically feasible. For patients with multiple tumors, systemic chemotherapy was given only if the general condition of the patient was satisfactory.
Statistical Analysis
In this study, major hepatectomy was defined as resection of 3 or more liver segments according to the Couinaud nomenclature. 15 Minor hepatectomy was defined as resection of 2 or fewer liver segments. Hospital mortality was defined as death during the period whereas the patient was in the hospital for the hepatectomy. All complications were prospectively recorded and the severity was graded by the Clavien-Dindo classification. 16 All HCCs were confirmed by histologic examinations. A positive resection margin was defined as the presence of tumor cells at the line of transection due to microscopic involvement by the main tumor, venous permeation or microsatellite nodules. A survival analysis was performed using the time of hepatectomy to the date of death or last follow-up. The end point of disease-free survival was recurrence of tumor or death (excluding hospital mortality). Seventeen patients in period 1 and 11 patients in period 2 had residual diseases at the time of hepatectomy. They were excluded in the disease-free survival analysis. The last censored date was 31 December 2009. Continuous variables were expressed as median (range) and compared between groups by the Mann-Whitney U test. Discrete variables were compared by the χ 2 test. Survival curves were computed using the Kaplan-Meier method and compared between groups by the log-rank test. The logistic regression analysis was performed to define factors that affected hospital mortality. Cox proportional hazard models were performed to define factors that determined the overall and disease-free survival rates. All statistical analyses were made using the statistical software (SPSS 16 for Windows, SPSS Inc, Chicago, IL). Statistical significance was defined as P < 0.05.
RESULTS
Comparison of the 2 groups of patients showed that patients in the period 2 were older and had a higher incidence of comorbid illness, but more patients in this group had asymptomatic tumors or tumors detected by screening ( Table 2 ). The liver function in terms of Child-Pugh classification, ICG retention rate and international normalized ratio was similar between the 2 groups. The preoperative serum albumin and creatinine levels were lower and the serum bilirubin level was higher among the patients in group 2.
In period 2, there were fewer patients with thoracic extension of skin incision. The incidence of tumor rupture, either spontaneous or iatrogenic, was lower among the patients in group 2. The need for major hepatectomy was also lower. For patients having right hepatectomy, the anterior approach was used predominantly in period 2 (28.6% vs 62%, P < 0.001). The ultrasonic dissector was used in almost all patients and the use of Pringle maneuver was limited to 16% of the patients in the second period ( Table 3) . The blood loss volume, transfusion volume, and the percentage of patients having blood transfusion were significantly lower in the patients in group 2 For the pathological status, although the tumor-nodemetastasis (TNM) staging 17 of the tumors of the 2 groups were similar, the patients in group 2 had smaller tumors ( Table 4 ). The incidence of microvascular invasion was similar. The incidence of a tumor involving the resection margin was lower in group 2. More patients in group 2 had underlying cirrhosis.
In the postoperative period, fewer patients in period 2 required mechanical ventilation. The complication rate was lower, especially for Clavien-Dindo grades IIIA and V severity. The hospital mortality rate of the patients in group 2 was significantly lower than that of the patients in group 1 (6.2% vs 3.1%, P = 0.012). The reduction in the hospital mortality rate was seen mostly in cirrhotic patients (7.8% vs 3.1%, P = 0.007). Both the ICU and hospital stay durations were shorter in group 2 ( Table 5 ).
By the logistic regression analysis, blood loss volume, and preoperative serum creatinine level were the significant factors affecting the hospital mortality in group 1, whereas the need for blood transfusion, preoperative serum creatinine level, age, and major hepatectomy were the significant factors for patients in group 2. For the entire group of patients, age [relative risk 1.047, 95% coincidence interval (CI) 1.018-1.076, P = 0.001], blood loss (relative risk 1.185, 95% CI 1.07-1.31, P = 0.001), the need for blood transfusion (relative risk 2.055, 95% CI 1.01-4.18, P = 0.047), preoperative serum creatinine level (relative risk 1.008, 95% CI 1.002-1.013, P = 0.007), and major hepatectomy (relative risk 2.26, 95% CI 1.023-4.992, P = 0.044) were the significant factors predicting hospital mortality.
Recurrence of tumors occurred in 78.2% of patients in group 1 and 60.2% of patients in group 2 (P < 0.001) after a median follow-up duration of 47.3 months and 35.4 months, respectively. The incidence of recurrence within the first year of hepatectomy and the pattern of recurrence were similar between the 2 groups (Table 6 ). For the treatment of intrahepatic recurrence, many more patients in group 2 had reresection of tumors. Chemoembolization was the main treatment method in the patients in group 1. Radiofrequency ablation replaced alcohol injection almost totally as the major ablation method in group 2. For the treatment of extrahepatic recurrence, the incidence of resection was the same and fewer patients in group 2 had systemic chemotherapy. The 1-, 3-, and 5-year overall survival rates of the patients in group 1 were 74.8%, 54.2%, and 42.1%, respectively and those of the patients in group 2 were 83.3%, 64.9%, and 54.8%, respectively (P < 0.001; Fig. 1A) . The 1-, 3-, and 5-year disease-free survival rates of the patients in group 1 were 53.1%, 33.2%, and 24%, respectively, and those of the patients in group 2 were 59.4%, 41.4%, and 34.8%, respectively (P = 0.0024; Fig. 1B ). In terms of TNM staging, higher overall survivals rates were observed in the patients with stages II, IIIA, and IVA diseases in group 2 ( Fig. 2A) . The disease-free survival rates were also significantly higher in the patients with TNM stages II and IIIA in group 2 (Fig. 2B) .
The survival analysis was performed with regard to the tumor status that was considered transplantable based on pathology findings. There was a significantly increased 5-year survival rate in the HCC patients with tumor status within the Milan criteria 18 from 62.7% in period 1% to 72.5% in period 2 (Fig. 3A) . A similar increase in the disease-free survival rate was seen (40.2% in group 1 and 49.2% in group 2; Fig. 3B ), although the difference did not reach statistical significance.
The survival analysis was performed with respect to the extent of hepatectomy. The median survival duration of the patients in group 2 having major hepatectomy was longer than that of the patients in group 1 (52.5 months vs 37.9 months, P = 0.0054; Fig. 4A ). A similar phenomenon was seen in patients having minor hepatectomy (100.3 months vs 56.83 months, P = 0.0002; Fig. 4B ). For disease-free survival, however, a significant increase was seen in patients having minor hepatectomy only (32 months vs 20 months, P = 0.0028; Figs. 4C, D).
Major hepatectomy was performed mostly in patients with TNM stage III and IV tumors (69.4% of group 1 and 70.5% of group 2). The overall 5-year survival rates of TNM stage III and IV patients having major hepatectomy of group 1 and 2 patients were 25.4% and 36.6%, respectively (P = 0.0034). The 5-year disease-free survival rate was also higher, in period 2 though the difference did not reach statistical significance (11.0% vs 19.5%, P = 0.0675).
The survival analysis was also performed in groups of patients with different underlying diseases. An improved overall survival rate was seen in the patients in group 2 who had underlying cirrhosis or normal liver (Fig. 5 ). For patients receiving treatments for their recurrences, the patients in group 2 had longer posttreatment survival, though the difference was not significant (Table 6 ). Further survival analysis was performed by grouping the patients into four 5-year sequential periods. A steady and significant improvement in the overall and disease-free survival rates was seen ( Fig. 6) . By univariate and multivariate analyses, blood loss volume (>2 L), tumor nodule number (>1), cirrhosis, venous invasion and TNM stage were the significant factors influencing the disease-free survival of the patients in group 1. For the patients in group 2, significant factors identified were symptomatic presentation, number of tumor nodule (>1), microvascular invasion, positive resection margin and TNM stage. For the entire group, symptomatic presentation, blood loss (>2 L), number of tumor nodule (>1), positive resection margin, microvascular invasion and TNM stage were the significant factors influencing the disease-free survival ( Tables 7 and 8 ).
Significant factors identified for predicting overall survival were similar to those for predicting disease-free survival except that the ICG retention rate (>14%) and development of postoperative complications were additional factors for groups 1 and 2, respectively. For the entire group, symptomatic presentation, blood loss volume (>2 L), postoperative complication, number of tumor nodule (>1), positive resection margin, venous invasion and TNM stage were the significant factors (Tables 8 and 9 ). In addition, the period in which the patients were operated was one of the determinants of survival. Patients operated in the second period had 61.5% longer median survival duration than that of the patients in the first period.
DISCUSSION
In this study, we demonstrated an improvement of the results of hepatectomy for HCC despite an older patient population, a higher incidence of comorbid illness, a higher incidence of cirrhosis, and worse liver function in patients operated in the second 10-year. The reduction in the hospital mortality rate was particularly obvious in cirrhotic patients. It was associated with less intraoperative bleeding and blood transfusion irrespective of the extent of hepatectomy, shorter ICU and hospital stays, and a lower complication rate. The improvement in the long-term survival was also observed in patients with underlying cirrhosis and even in patients with advanced TNM stages who underwent major hepatectomy. Because the operations were performed by the same team of surgeons, the accumulated experience was definitely a contributory factor but constant attention to refinement of the surgical technique and perioperative care were important reasons.
With strict selection of HCC patients for hepatectomy basing on their liver function, preoperative renal function became an important factor influencing hospital mortality. Careful scrutiny of patients' renal function was therefore mandatory. Patients with impaired renal function should be cared in the ICU for fluid balance control and considered for perioperative hemodialysis. Blood loss was also identified consistently to be an important factor predisposing to hospital mortality. Bleeding usually occurred during liver transection. Thus, the Pringle maneuver was a routine procedure in our early series and is currently used in many centers. [19] [20] [21] However, in our recent practice, the Pringle maneuver has not been used routinely during liver transection because we found that without the time constraint of the Pringle maneuver, liver transection is unhurried and precise. Without the Pringle maneuver, a lower bleeding and transfusion volume can actually be achieved even in patients undergoing major hepatectomy. The reduction in bleeding volume is accomplished by the cautious and slow application of the ultrasonic dissector and the restriction of intravenous fluid infusion to reduce the central venous pressure. However, older patients are at a higher risk of having more bleeding during liver transection because it is difficult to maintain normal blood pressure with a low central venous pressure. Patients with renal impairment have a higher risk of postoperative renal failure if fluid infusion is restricted. We have also observed that a low central venous pressure is ineffective because tumor compression on the hepatic veins or iatrogenic and premature division of the outflow tract are responsible for liver congestion. In such situations, Pringle maneuver is employed to achieve rapid liver transection and minimum blood loss.
The incidence of postoperative complication remained high, even though it was lower in the second period. Considering the nature of the operation, postoperative complications seemed inevitable. However, with careful postoperative management and possibly improved technique, the incidence of complications, particularly Clavien-Dindo grades IIIa and V severity, were reduced in period 2. Infection remained an important cause of rapid deterioration of liver function of HCC patients after hepatectomy. In our current protocol, systemic antibiotic is normally given for 3 to 5 days despite the sterile nature of the operation because contamination may occur during the operation and presence of a thin layer of ischemic liver at the transection site, though minimal, may be the source of occult infection. Pneumonia is the most common infection and should be prevented at all costs. Once a sign of infection appeared, we modified the antibiotic protocol promptly and looked for the source of infection. If hyperglycemia was noted, tight blood glucose control was considered mandatory. 11 With early intervention, further deterioration could be withheld. However, control of infection is possible only if the liver function is preserved. That attests the need for preservation and protection of the liver remnant during the operation. 5, 7 Pathologic characteristics of the tumor such as microvascular invasion, multiplicity, and TNM stage remain the major determinants of long-term survival. In this study, solitary tumor was associated with favorable prognosis but tumor size was not a significant factor. Thus, the higher incidence of smaller tumors in the patients in group 2 could not account for better survival rates. A further implication is that hepatectomy for a solitary tumor irrespective of the tumor size is a worthwhile procedure. 22, 23 Large tumors, however, frequently impinge on the major hepatic veins or the liver hilum. Resection of a large tumor yet preserving blood supply and venous drainage of the remnant liver is feasible as long as high quality CT or magnetic resonance imaging is available for careful planning of the operation. Restoration of the portal vein and hepatic vein is possible nowadays with conduits such as the cryopreserved vein or ringed Gor-Tex graft.
In the second period of the study, more patients presented with asymptomatic tumors that were detected by screening. They had higher survival rates. On the contrary, patients with symptomatic presentation had less favorable survival outcomes. In these patients, symptoms were produced because of the rapidly increasing tumor size related to fast tumor growth or intratumoral bleeding, both indicative of aggressive biological behaviors. Fortunately, the incidence of ruptured HCC being associated with even worse prognosis was lower in period 2. To offer the patients the maximum survival benefits, we operated on symptomatic patients early and avoided intraoperative tumor rupture. 24 Thus, the overall survival duration of symptomatic patients was longer in the second period (Table 9 ). A similar increase in the survival rate was also observed in asymptomatic patients (Table  9 ). Hence, a higher incidence of asymptomatic patients in the second period may not be an important reason for the improvement of the results.
Blood loss volume was consistently found to influence the long-term survival in the first period, but with meticulous efforts to reduce bleeding, blood loss volume was not a significant factor in the second period. Blood transfusion, however, is still needed in some patients with difficult hepatectomy. Unlike the pathological factors, bleeding, and transfusion are surrogate markers of technical factors that can be modified. 25 Another technical factor is the tumor-free resection margin. Positive resection margin, though lower in incidence in period 2 of the current study, has a profound influence on the long-term survival. The width of the macroscopic tumor-free resection margin needed to avoid microscopic positive resection margin and local recurrence is controversial. There are suggestions that the width of the tumor-free resection margin is irrelevant because HCC is potentially multifocal and microscopic involvement of the margins is related to the aggressive behaviors of the tumor. [26] [27] [28] Moreover, tumors encroaching the major hepatic vein or the portal pedicle may not have sufficient tumor-free resection margins if preservation of the remnant liver volume is needed. Yet, meticulous attention to achieve tumor free resection margin in situations other than those involving the liver hilum seems warranted.
Postoperative complications did influence the overall longterm survival rate. The exact reason is not known. It is not impossible that complications such as bleeding and infection are frequently associated with systemic inflammatory response. The latter phenomenon may produce a favorable microenvironment in the liver remnant and extrahepatic organs for circulating cancer cells to deposit and grow. 29 Septic complications, therefore, must be prevented at all costs. To prevent cancer cell disseminating into the systemic circulation, the "no touch" technique such as the anterior approach right hepatectomy is preferred. 23 The anterior approach is also applicable to left liver resection. 30 Both the disease-free and overall survival rates have improved but the overall survival rate was much higher than the disease-free survival rate in the second period even for late TNM stage diseases. This was due to our aggressive treatment for both intra-and extrahepatic recurrences. Treatment of recurrence is more likely to be associated with better outcomes if the recurrence is small and few and treatment is prompt. Only a close follow-up and surveillance imaging can detect early recurrence. However, the median survival duration of patients treated for their recurrence was not significantly longer than patients in group 1. This implies that the current liver tumor ablation treatment (including radiofrequency ablation and chemoembolization) cannot completely control all tumor growth or prevent further recurrences and their efficacy has not changed over the years. Further studies to refine local ablation treatments and design of strategies to eradicate microscopic tumor foci are needed.
In this study, hepatitis B is the predominant cause of HCC, whereas hepatitis C and alcoholism are rare etiologies. Thus, it is impossible to demonstrate whether improvement of results occurred in patients with etiologies other than hepatitis B. Nevertheless, compared with the reported series with hepatitis C as the predominant etiology, the results of the current series seemed more favorable. 31 Availability of effective treatments of hepatitis B may account for the difference. 32 The other deficiencies of this study are the possibility of lead-time bias and the inability to classify patients preoperatively into the Milan criteria accurately. With improved imaging modalities, accurate classification of tumor staging is anticipated. 33 In summary, a continuous improvement of hospital mortality and long-term survival results was observed in the past 20 years in HCC patients having hepatectomy. The improvement is in pace with that of liver transplantation for HCC. 34 The overall survival rate of patients with tumor status that is considered transplantable after hepatectomy is comparable with that accomplished by liver transplantation. 35 Although the disease-free survival rate of such patients is far below that of the transplant patients, prompt treatment of recurrence detected by vigorous postoperative surveillance did result in long-term survival. Thus, hepatectomy should remain the treatment of choice for resectable HCC and preserved liver function in regions with deceased organ scarcity. Improvement of survival was also observed in patients with advanced diseases. The 5-year overall survival rates of 81.7%, 77.2%, 44%, and 28.2% for TNM stages I, II, IIIA, and IVA patients after hepatectomy, respectively, may become the current standard. Further improvement of results depend on technical refinement to reduce blood loss to the minimum, avoid blood transfusion, preserve liver remnant function, secure tumor-free resection margins, and meticulous perioperative care to reduce complications. Life-long surveillance for recurrence and prompt treatment are mandatory but development of more effective local ablation methods are needed to lengthen postrecurrence survival.
